The Progressive Supranuclear Palsy Clinical Deficits Scale.
Piot I, Schweyer K, Respondek G, Stamelou M, Gasser T, Hermann A, Hoeglinger G, Hoellerhage M, Kimmich O, Klockgether T, Levin J, Machetanz G, Osterrath A, Palleis C, Prudlo J, Spottke A, Berg D, Buerk K, Classen J, Eggers C, Greuel A, Grimm MJ, Hermann L, Iankova V, Jahn K, Jost W, Klietz M, Kuehn A, Marxreiter F, Paschen S, Poetter-Nerger M, Preisl MT, Prilop L, Toenges L, Trenkwalder C, Warnecke T, Wegner F, Winkler J, Antonini A, Bhatia KP, Boxer AL, Colosimo C, Compta Y, Corvol JC, Golbe LI, Hoglinger GU, Lang AE, Litvan I, Morris HR, Nilsson C, Pantelyat A, Respondek G, Stamelou M, Sckopke P, Schenk T, Goetz CG, Stebbins GT (2020)
Publication Type: Journal article
Publication year: 2020
Journal
Book Volume: 35
Pages Range: 650-661
Journal Issue: 4
DOI: 10.1002/mds.27964
Abstract
BACKGROUND: There is currently no undisputed, validated, clinically meaningful measure for deficits in the broad spectrum of PSP phenotypes. OBJECTIVE: To develop a scale to monitor clinical deficits in patients with PSP across its broad phenotypes. METHODS: The Progressive Supranuclear Palsy Clinical Deficits Scale was conceptualized to cover seven clinical domains (Akinesia-rigidity, Bradyphrenia, Communication, Dysphagia, Eye movements, Finger dexterity, and Gait & balance), each scored from 0 to 3 (no, mild, moderate, or severe deficits). User guidelines were developed to standardize its application. Progressive Supranuclear Palsy Clinical Deficits Scale scores were collected in patients fulfilling the MDS-PSP diagnostic criteria in two independent, multicenter, observational studies, both cross-sectionally (exploratory DescribePSP cohort; confirmatory ProPSP cohort) and longitudinally (12-months' follow-up, both cohorts). RESULTS: Cognitive pretesting demonstrated easy scale utility. In total, 164 patients were scored (70.4 ± 7.6 years; 62% males, 35% variant phenotypes). Mean Progressive Supranuclear Palsy Clinical Deficits Scale completion time was 4 minutes. The Progressive Supranuclear Palsy Clinical Deficits Scale total score correlated with existing scales (e.g., Progressive Supranuclear Palsy Rating Scale: R = 0.88; P < 0.001). Individual Progressive Supranuclear Palsy Clinical Deficits Scale items correlated well with similar constructs in existing scales. Internal consistency (Cronbach's alpha: 0.75), inter-rater reliability (0.96), and test-retest stability (0.99) were acceptable. The PSP-CDS showed significant 12-month change (baseline, 8.6 ± 3.6; follow-up: 10.8 ± 3.6; annualized difference: 3.4 ± 3.4; n = 49; P < 0.0001). Sample sizes required per arm for a two-arm, 1-year follow-up therapeutic trial to detect 50% change in Progressive Supranuclear Palsy Clinical Deficits Scale progression was estimated to be 65 (two-sided, two-sample t test). CONCLUSION: The Progressive Supranuclear Palsy Clinical Deficits Scale is a rapidly completed, clinimetrically sound scale for clinical care and research involving PSP. © 2020 International Parkinson and Movement Disorder Society.
Involved external institutions
Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE)
Germany (DE)
National and Kapodistrian University of Athens
Greece (GR)
Rush University
United States (USA) (US)
Ludwig-Maximilians-Universität (LMU)
Germany (DE)
Germany (DE)
National and Kapodistrian University of Athens
Greece (GR)
Rush University
United States (USA) (US)
Ludwig-Maximilians-Universität (LMU)
Germany (DE)
How to cite
APA:
Piot, I., Schweyer, K., Respondek, G., Stamelou, M., Gasser, T., Hermann, A.,... Stebbins, G.T. (2020). The Progressive Supranuclear Palsy Clinical Deficits Scale. Movement Disorders, 35(4), 650-661. https://doi.org/10.1002/mds.27964
MLA:
Piot, Ines, et al. "The Progressive Supranuclear Palsy Clinical Deficits Scale." Movement Disorders 35.4 (2020): 650-661.
BibTeX: Download